Illumina Settles Icahn Suit Over Grail Deal

Delaware Chancery Court approved a settlement tied to Illumina's failed $8 billion acquisition of cancer detection firm Grail.

Updated on Nov. 3, 2026 in Healthcare

Illumina Settles Icahn Suit Over Grail Deal

Delaware Chancery Court approved a settlement between Carl Icahn's investment companies and Illumina's former corporate leaders, ending Delaware litigation over the company's failed $8 billion deal to acquire Grail. The court had days earlier thrown out a consolidated shareholder case raising parallel claims.

Why it matters

The settlement closes a legal dispute over a transaction that U.S. and European authorities rejected, forcing Illumina to unwind the Grail merger. Shareholder suits alleged the company's then-CEO and directors closed the deal despite active regulatory scrutiny, a claim now resolved in part for Delaware residents and businesses that depend on the state's corporate courts.

The failed Grail deal carried an $8 billion valuation, and the court's approval resolves Delaware litigation tied to it. The financial terms of the settlement were not specified in the available details.

The players

Carl Icahn

Carl Icahn is a billionaire investor known for activist campaigns, whose investment companies reached the settlement with Illumina's former leaders.

Illumina

Illumina is a San Diego-based genomics company that sought to acquire cancer detection firm Grail for $8 billion before regulators blocked the deal.

The details

Illumina closed the Grail transaction while regulatory reviews were active in the United States and Europe. A U.S. judge and European antitrust authorities both rejected the merger, leaving the company to unwind it.

Late October 2026: Delaware Chancery Court threw out a consolidated shareholder case.
Monday, week of November 3, 2026: Chancery Court approved the Icahn-Illumina settlement.

Market Landscape

The Illumina-Grail collapse highlights how antitrust review on two continents can unwind large healthcare and diagnostics deals after closing. The settlement shows how post-merger shareholder litigation in Delaware can continue long after regulators have acted.

Delaware-based corporate litigation over failed health-sector mergers can take years to resolve and may shape how boards handle regulatory risk. Shareholders in companies pursuing large acquisitions should watch whether closing deals amid pending antitrust review draws legal challenges.

The takeaway

Closing a major acquisition while regulators are still reviewing it can expose leadership to lasting legal liability even after the deal is unwound. Delaware's Chancery Court remains a central forum for resolving these disputes between investors and corporate leaders.